No profile data available.
Eton Pharmaceuticals, Inc. (ETON) is a healthcare company in the additional hormone and metabolic drugs industry, based in Deer Park, United States, with about 44 full-time employees.
It reported revenue of $79.95 million for fiscal year 2025, up 104.9% from fiscal year 2024, and net income of -$4.60 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $37.59 million, up 98.6% from a year before. Its market capitalization was $1.58 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Eton Pharmaceuticals reported $79.95 million in revenue for fiscal year 2025, up 104.9% from $39.01 million in fiscal year 2024. In Q2 2026 revenue was $37.59 million.
$1.58 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Amylyx Pharmaceuticals, Inc. (AMLX), MBX Biosciences, Inc. (MBX), Xeris Biopharma Holdings, Inc. (XERS), Immix Biopharma, Inc. (IMMX).